10.11.2023 - Procedure started

EMA’s human medicines committee (CHMP) has started a review of systemic medicines (given by mouth or by injection) that contain the antibiotic azithromycin. Antimicrobial resistance (AMR) against azithromycin is increasing in the European Union (EU). Therefore, and in view of the broad use of these medicines, a re-evaluation of the benefits and risks of azithromycin in its many authorised uses is considered warranted to optimise its use and minimise the risk of AMR development.

Further information

For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):